• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于微环境 pH 调节固体分散体,肠溶性和亲水性聚合物可提高难溶性酸性药物的溶解和吸收。

Enteric and hydrophilic polymers enhance dissolution and absorption of poorly soluble acidic drugs based on micro-environmental pH-modifying solid dispersion.

机构信息

The Department of Veterinary Parasitology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; NMPA Key Laboratory for Research and Evaluation of Generic Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.

The Department of Veterinary Parasitology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; Institute of Animal Quarantine, Chinese Academy of Inspection and Quarantine, Beijing 100176, China.

出版信息

Eur J Pharm Sci. 2022 Jan 1;168:106074. doi: 10.1016/j.ejps.2021.106074. Epub 2021 Nov 16.

DOI:10.1016/j.ejps.2021.106074
PMID:34798261
Abstract

The oral bioavailability of poorly water-soluble active pharmaceutical ingredient (API) is often inadequate for the desired therapeutic effect. Micro-environmental pH-modifying solid dispersion (micro pHm SD) is an effective method for enhancing the dissolution of pH-dependent soluble APIs. However, erratic bioavailability of these drugs was often found when the micro pHm SD of the drugs was orally administrated and passed through the gastrointestinal tract. Because the added alkalizer in micro pHm SD could be neutralized by the acid in the stomach, as a result not enough alkalizer is left to form alkaline micro-environment around the drug in the intestine, leading to poor dissolution and bioavailability of API. Enteric polymers are applicable materials for site-specific drug delivery that are insoluble in gastric tract but soluble in the intestine targeted for drug release. In this study, a poorly water-soluble model drug, toltrazuril (TOL), was prepared as enteric micro pHm SD with enteric, hydrophilic polymers and alkalizer. The surface of enteric micro pHm SD tablets staining and alkalizer protection test in the acid dissolution medium qualitatively and quantitatively confirmed the protective effects of the enteric polymer on the alkalizer. Dissolution studies revealed that the drug release from the enteric micro pHm SDs was improved significantly compared with micro pHm SD with no enteric polymer. The pH-dependent solubility of enteric polymer had effects on the dissolution of APIs from the SDs in neutral medium. Enteric micro pHm SDs with higher proportion of enteric polymer showed higher C and dissolution rate of TOL. The physicochemical characterization and the molecular interaction between drug and matrix were analyzed by electron microscopy (SEM), differential scanning calorimetry (DSC), and fourier transform infrared spectroscopy (FTIR), finding that the formation of hydrogen bonds between TOL and matrix was helpful to promote dissolution of TOL. Ca(OH)-TOL-PVPk30-HPMCAS 8: 8: 18: 6 was determined as the most optimal enteric micro pHm SD, which significantly improved the bioavailability of TOL and its active metabolism (TOLSO, TOLSO) in pharmacokinetic study and could effectively reduce the irritation of the gastrointestinal mucosa caused by the alkalizer Ca(OH) when the SD was orally administrated to rabbits. The present study demonstrates that formulating APIs with poor water solubility as enteric micro pHm SD is an effective method for protecting the alkalizer in SD and improving the dissolution of APIs and the bioavailability following oral administration.

摘要

对于水溶性差的活性药物成分 (API),其口服生物利用度往往不足以为达到预期的治疗效果。微环境 pH 调节固体分散体 (micro pHm SD) 是提高 pH 依赖性可溶性 API 溶解的有效方法。然而,当这些药物的 micro pHm SD 经口给药并通过胃肠道时,其生物利用度往往不稳定。因为 micro pHm SD 中添加的碱化剂会被胃中的酸中和,因此在肠道中没有足够的碱化剂形成药物周围的碱性微环境,导致 API 的溶解和生物利用度差。肠溶性聚合物是适用于局部给药的材料,它们在胃中不溶但在靶向释放药物的肠道中溶解。在这项研究中,将一种水溶性差的模型药物托曲珠利 (TOL) 制备成具有肠溶性、亲水性聚合物和碱化剂的肠溶性 micro pHm SD。肠溶性 micro pHm SD 片剂在酸性溶出介质中的表面染色和碱化剂保护试验定性和定量证实了肠溶性聚合物对碱化剂的保护作用。溶出研究表明,与无微溶性聚合物的 micro pHm SD 相比,药物从肠溶性 micro pHm SD 的释放得到了显著改善。肠溶性聚合物的 pH 依赖性溶解度对中性介质中 SD 中 API 的溶解有影响。具有较高比例肠溶性聚合物的肠溶性 micro pHm SD 显示出更高的 TOL 的 C 和溶解速率。通过电子显微镜 (SEM)、差示扫描量热法 (DSC) 和傅里叶变换红外光谱 (FTIR) 分析了药物与基质之间的物理化学特性和分子相互作用,发现 TOL 与基质之间氢键的形成有助于促进 TOL 的溶解。Ca(OH)-TOL-PVPk30-HPMCAS 8:8:18:6 被确定为最理想的肠溶性 micro pHm SD,它显著提高了 TOL 的生物利用度及其在药代动力学研究中的活性代谢物 (TOLSO、TOLSO),并且可以有效地减少 SD 口服给予兔子时碱化剂 Ca(OH) 引起的胃肠道黏膜刺激。本研究表明,将水溶性差的 API 制成肠溶性 micro pHm SD 是保护 SD 中碱化剂、提高 API 溶解度和口服给药后生物利用度的有效方法。

相似文献

1
Enteric and hydrophilic polymers enhance dissolution and absorption of poorly soluble acidic drugs based on micro-environmental pH-modifying solid dispersion.基于微环境 pH 调节固体分散体,肠溶性和亲水性聚合物可提高难溶性酸性药物的溶解和吸收。
Eur J Pharm Sci. 2022 Jan 1;168:106074. doi: 10.1016/j.ejps.2021.106074. Epub 2021 Nov 16.
2
Effect of micro-environment modification and polymer type on the in-vitro dissolution behavior and in-vivo performance of amorphous solid dispersions.微环境修饰和聚合物类型对无定形固体分散体体外溶出行为及体内性能的影响。
Eur J Pharm Sci. 2017 Jun 15;104:240-254. doi: 10.1016/j.ejps.2017.04.007. Epub 2017 Apr 13.
3
Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion.通过分子相互作用以及在固体分散体中用碱化剂调节微环境pH值来提高埃索美拉唑的胃稳定性。
Int J Pharm. 2017 May 15;523(1):189-202. doi: 10.1016/j.ijpharm.2017.03.047. Epub 2017 Mar 23.
4
Pharmacokinetics of toltrazuril and its metabolites after oral and parenteral administration of novel oil-based suspension based on micro-environmental pH-modifying solid dispersion in rabbits.口服和肠胃外给予新型基于微环境 pH 调节固体分散体的油基混悬剂后托曲珠利及其代谢物的药代动力学研究在兔体内的研究
Vet Parasitol. 2021 Nov;299:109580. doi: 10.1016/j.vetpar.2021.109580. Epub 2021 Sep 21.
5
A novel oil-based suspension of a micro-environmental, pH-modifying solid dispersion for parenteral delivery: Formulation and stability evaluation.一种新型油基混悬型微环境 pH 调节剂固体分散体的制备及其稳定性评价。
Colloids Surf B Biointerfaces. 2019 Jul 1;179:382-392. doi: 10.1016/j.colsurfb.2019.04.001. Epub 2019 Apr 3.
6
Microenvironment pH modified solid dispersion of Toltrazuril as a new strategy to improve the treatment of experimental Apicomplexan infection.托曲珠利微环境pH修饰固体分散体作为改善实验性顶复门原虫感染治疗的新策略。
Acta Trop. 2023 Feb;238:106797. doi: 10.1016/j.actatropica.2022.106797. Epub 2022 Dec 14.
7
Formulation and Evaluation of a Novel Oral Oil-Based Suspension Using Micro-environmental pH-Modifying Solid Dispersion.新型口腔油基混悬剂的制剂与评价——利用微环境 pH 调节固体分散体技术。
AAPS PharmSciTech. 2019 Jan 10;20(2):75. doi: 10.1208/s12249-018-1222-x.
8
Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.微环境pH调节的固体分散体用于提高难溶性弱碱性GT0918(一种正在研发的抗前列腺癌药物)的溶出度和生物利用度:制备、表征及体内评价
Int J Pharm. 2014 Nov 20;475(1-2):97-109. doi: 10.1016/j.ijpharm.2014.08.047. Epub 2014 Aug 27.
9
Enhanced dissolution and oral bioavailability of valsartan solid dispersions prepared by a freeze-drying technique using hydrophilic polymers.采用冷冻干燥技术,使用亲水性聚合物制备的缬沙坦固体分散体的溶出度和口服生物利用度提高。
Drug Deliv. 2016;23(1):41-8. doi: 10.3109/10717544.2014.903012. Epub 2015 Sep 4.
10
Toltrazuril alkalizer-modifying solid dispersions against Toxoplasma gondii: A pharmacotechnical strategy to improve the efficacy of the drug.托曲珠利碱化固体分散体抗弓形虫:提高药物疗效的药剂学策略。
Eur J Pharm Sci. 2023 Dec 1;191:106613. doi: 10.1016/j.ejps.2023.106613. Epub 2023 Oct 18.

引用本文的文献

1
Design of Experiment Approach for Enhancing the Dissolution Profile and Robustness of Loratadine Tablet Using D-α-Tocopheryl Polyethylene Glycol 1000 Succinate.使用琥珀酸聚乙二醇1000维生素E醋酸酯提高氯雷他定片溶出度曲线和稳健性的实验设计方法
Pharmaceutics. 2025 Mar 17;17(3):380. doi: 10.3390/pharmaceutics17030380.
2
Formulation and Evaluation of pH-Modulated Amorphous Solid Dispersion-Based Orodispersible Tablets of Cefdinir.头孢地尼pH调节型非晶态固体分散体口腔崩解片的处方设计与评价
Pharmaceutics. 2024 Jun 27;16(7):866. doi: 10.3390/pharmaceutics16070866.